SCHEMBL5083576

SCHEMBL5083576

CC(=O)C(c1ccccc1)S(=O)(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 3/20 0.70
ACP1 P24666 8/20 0.49
PTPN1 P18031 3/20 0.49
PTPN6 P29350 3/20 0.49
PTPN11 Q06124 3/20 0.49
PTPN12 Q05209 3/20 0.49
ALDH1A1 P00352 2/20 0.47
PTPN7 P35236 2/20 0.45
PTPN13 Q12923 2/20 0.45
SSU72 Q9NP77 2/20 0.45
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GMNN O75496 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
PMP22 Q01453 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6914825 0.85 SRC (0.55) SRCACP1PTPN1PTPN6PTPN11
SCHEMBL27829711 0.83 SRC (0.53) SRCACP1PTPN1PTPN6PTPN11
SCHEMBL7168498 0.83 SRC (0.53) SRCACP1PTPN1PTPN6PTPN11
SCHEMBL20869602 0.83 SRC (1.00) SRCACP1PTPN1PTPN6PTPN11
SCHEMBL9912818 0.83 SRC (1.00) SRCACP1PTPN1PTPN6PTPN11
SCHEMBL11166146 0.83 SRC (1.00) SRCACP1PTPN1PTPN6PTPN11
SCHEMBL28144339 0.82 SRC (0.52) SRCACP1PTPN1PTPN6PTPN11
SCHEMBL6408416 0.82 SRC (0.62) SRCACP1PTPN1PTPN6PTPN11
SCHEMBL13281779 0.82 SRC (0.52) SRCACP1PTPN1PTPN6PTPN11
SCHEMBL27750137 0.81 SRC (0.61) SRCACP1PTPN1PTPN6PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180170861-A1 SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USED THEREOF INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2018-06-21 US disclosed
EP-1718599-A4 SYNTHESIS OF STERICALLY HINDERED SECONDARY AMINOETHER ALCOHOLS EXXONMOBIL RES & ENG CO (US) 2008-06-25 EP disclosed
EP-1718599-A1 SYNTHESIS OF STERICALLY HINDERED SECONDARY AMINOETHER ALCOHOLS ExxonMobil Research and Engineering Company (US) 2006-11-08 EP disclosed
WO-2005082835-A1 SYNTHESIS OF STERICALLY HINDERED SECONDARY AMINOETHER ALCOHOLS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170861-A1 SMALL MOLECULE INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES AND USED THEREOF PTPA, EPM2A, PTPRA SRC 201/4885ACP1 66/4885PTPN1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.